公司资料
Adial Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- ADIL
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
4.99 USD (+25.38%)
收盘价
最后更新: 2026年8月17日
5.06M USD
市值
股价为何变动
As of Aug 17, 2026, ADIL closed up 25.4% at $4.99. No new same-company headline was identified in the current news window.
公司概览
业务概览
Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.
所在地与行业分类
Adial is headquartered in the United States and listed on NASDAQ, with a small-cap specialty-biopharma profile. It sits in addiction medicine rather than mainstream oncology or immunology.
商业模式特征
The business depends on clinical progress, regulatory strategy, and the ability to show that its candidate can create a meaningful treatment option in addiction care. Investors usually watch proof-of-concept data, safety, and commercialization potential.
生物医药行业定位
Adial occupies a niche addiction-medicine position within biotech. The stock is catalyst-sensitive because the company is still trying to prove a focused therapeutic thesis in a difficult indication.
未来催化剂
- Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive. The company still needs a stronger human signal.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。